Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00841217
Registration number
NCT00841217
Ethics application status
Date submitted
10/02/2009
Date registered
11/02/2009
Date last updated
11/02/2009
Titles & IDs
Public title
Regulation of Lipoprotein Transport in Metabolic Syndrome
Query!
Scientific title
Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome
Query!
Secondary ID [1]
0
0
UWA_PHR022009
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Obesity
0
0
Query!
Lipid Disorders
0
0
Query!
Cardiovascular Disease
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GW501516
Placebo comparator: 1 - placebo group
Active comparator: 2 - GW501516, 2.5mg
Treatment: Drugs: GW501516
2.5mg/day
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
ApoB transport rate
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
5 weeks
Query!
Secondary outcome [1]
0
0
ApoA and C-III transport rate
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
5 weeks
Query!
Eligibility
Key inclusion criteria
* Any three of the following:
* Waist circumference > 102 cm
* Triglycerides > 150 mg/dL
* HDL-cholesterol < 40 mg/dL
* Blood glucose > 110 mhg/dL
* Blood pressures > 130/85 mmHg
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Triglycerides > 500 mg/dL
* Diabetes mellitus
* CVD
* Consumption of > 30 g alcohol/day
* Use of agents affecting lipid metabolism
* APOE2/E2 genotype
* Creatinemia (> 120 umol/L)
* Hypothyroidism
* Abnormal liver and muscle enzymes
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
13
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
0
0
University of Western Australia - Perth
Query!
Recruitment postcode(s) [1]
0
0
6000 - Perth
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
The University of Western Australia
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
National Heart Foundation, Australia
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable effect on lipoprotein metabolism.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00841217
Query!
Trial related presentations / publications
Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab. 2011 Oct;96(10):E1568-76. doi: 10.1210/jc.2011-1131. Epub 2011 Aug 3.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00841217
Download to PDF